Kelsey N. Lamb

The paper develops covalent inhibitors targeting the RAS binding domain of PI3Kα, showing efficacy against RAS and HER2-driven tumors without affecting glucose homeostasis.

This study determines the structural basis for CDY chromodomain selectivity in binding lysine-methylated ARKS motifs, revealing distinct preferences for H3K9me3 and H3K27me3.